Uncategorized
Phase 3 study shows Dextenza resolves pain, inflammation quicker than placebo
LOS ANGELES — The results of a third phase 3 study comparing the safety and efficacy of a sustained-release dexamethasone insert vs. a placebo for postoperative cataract surgery patients showed a statistically significant superiority for postoperative absence of pain and inflammation, according to a speaker here.“Dextenza (sustained-release dexamethasone intracanalicular depot, Ocular Therapeutix) showed a statistically significant improvement as early as day 2 for pain and day 4 for inflammation,” Eric D. Donnenfeld, MD, said at the American Society of Cataract and Refractive Surgery meeting.